Objeclive: To determine the prevalence of antibod~ to .~d risk ~actors for Hepatitis A virus (HA V) in individuals attending three intellectual disability services.
Introduction HA V causes an acute self-limiting disease. It is transmitted via the faecal-oral route, and is most common in the areas of the world with poor sanitation. The clinical severity of HA V infection increases with age. Childhood infection is usually quite mild. the majority of children under 5 years showing no symptoms, but people infected as adults can suffer severe and prolonged illness. Hospitalisation and mortality rates increase with age I,
The seroprevalence of HA V has been declining in most parts of the world in recent decades, probably due to improvements in living standards 2 A population based prevalence survey in 1991 in an Irish town found a population immunity level to HAV of 43%, with immunity increasing with age 6 . A study of Irish international travellers over a six year period (1986) (1987) (1988) (1989) (1990) (1991) showed that over half (54%) those surveyed were immune 7 while a study of general practice attendees in Ireland over a three year period (1993) (1994) (1995) (1996) found an immunity level of 67% 8 • A 1982 study reported that the prevalence of HA V antibody in residents in institutions for intellectual disability was higher than in the general population 9. This was attributed to suboptimal hygiene in institutionalised settings 10 . An Irish seroprevalence surver in a nonresidentialleaming disability setting found a 70% prevalence in the early 19905 I . However, screening in three Irish intellectual disability schools found an overall prevalence level of HAV antibody of 10010 in 1999 among three to eighteen year olds 12. Individuals with Down syndrome have been reported to have a higher prevalence than other forms of intellectual disability 9, I) Factors reported previously to be associated with anti-HA V positivity include age 10, 1)·17 and duration of institutionalisation 10,1), IS,I7, However, Gil 18 et al. found age or length of institutionalisation did not influence prevalence of antibody in a country of intermediate endemicity,
Recent immunisation guidelines in Ireland recommend that patients and carers in institutions for those with intellectual disability (including day care facilities) receive hepatitis B vaccine and further recommend that staff and residents in institutions for learning disabilities may be considered for immunisation with hepatitis A vaccine 19. A review of cost-effectiveness of hepatitis A vaccine in children, adolescents and adults in developed countries concluded that hepatitis A vaccination is likely to be cost effective in institutions 20, A systematic review of evidence of risk of infection with HA V among risk groups including institutionalised subjects concluded that there is moderate evidence of risk of contracting HA V among institutionalised subjects 21 , They recommended that the decision to vaccinate should be made locally on the basi s of the home or community's ability to maintain adequate standards of hygiene 21, Similarly, guidelines for England and Wales state that HA V vaccination should be considered for those individuals with special needs whose capacity to maintain good standards of hygiene is limited, and their carers, following a risk assessment 22. This study was carried out to clarify the need for hepatitis A vacc ination in this population.
The aims of the study were to : a) To detennine the prevalence of HAV antibodies (IgG) in individuals attending three intellectual disability services b) To document factors associated with prevalence and c) To provide infonnation for planning of future vaccination programmes.
This study was carried out between April 2003 and January 2004.
Methods Study population
The study was carried out in three large centres for people with an intellectual disability in Dublin. All three centres provide a service for all levels of intellectual disability.
Sample size
The sample was chosen to ensure that a 95% confidence interval around an estimated seroprevalence of 50% would be +1-5%. The sample was as follows: All residents on the campus (178) of institution A, and all individuals ( 148) resident in institution C, were invited to take part. in institution B, which is a multicentred institution, a random computer-generated sample of 600 people (of 1420 who were emolled in the institution) was invited to take part. They a ll attended a service on a daily basis and some of them were living in community residentia l settings. 926 individuals from the three institutions were invited to participate Eligibility criteria were:
• No documented previous hepatitis A vaccination.
• No immunoglobulin administered in the previous six: months.
Written consent to participate was obtained from the parents/guardians, and the client where possible. The consent fonn ex:plained the purpose of the study in writing (Appendix 1).
Study instruments

Questionnaires
We used a questionnaire to obtain basic demographic data and other infonnation relevant to the spread of HA V from each client's medical records (Appendix 2). The questionnaires did not record name or address but had a personal identifier and date of birth. Each institution also had to complete a brief questionnaire on total numbers of people in the institution and on whether any outbreaks of HA V had occurred there (Appendix 3). The questionnaires were piloted for comprehension.
Laboratory
Oral fluid was collected according to the manufacturer's instructions for analysis for hepatitis A antibody. These samples recorded the client 's name, personal identifier and date of birth and were sent to the National Virus Reference Laboratory (NVRL) for analysis for hepatitis A IgG antibody. Measurement of anti-HAY (lgG antibody) using an antibody capture enzyme immunoassay (EIA) technique from the oral fluid samples was undertaken using a modification of a method used previously in the same laboratory which included specimen 
Analysis
Analysis (chi square test (i) and logistic regression) was carried out using the statistical package R 24.
•
Results
The response rate was 69 % (636/926) overall. There was no recor~ ~fany of,the participants being given immunoglobulin (in the previous six months) or hepatitIs A vaccme (ever) so all questionnaires were eligible for inclusion. No outbreaks of HA V were known ,10 ha~e occurred in any of the services. Not all questions were answered, and so the denommator IS below 636 for some results. The response rate by institution was as follows: 73% (130/ 178) in institution A, 69% (415/600) in institution Band 61% (91 / 148) in institution C. Ninety five percent afthe non-responders did not return the fonn with the remaining 5% saying no.
The median age of responders was 36 years and of non-responders, 38 years (p=O.06, Wilcoxon rank-sum test). Further analysis showed a strong interaction between age and institution, ti. = 26.8, p = 2.8e·7). For this reason, analysis of non·response was done separately for each institution. The response rate by age and gender by institution is shown in Table I . The questions: length of time in this institution (years) and length of time in other institutions combined (years) were not reliably recorded and were therefore excluded from analysis.
5
HA V antibody level There were 635 oral fluid samples received. The overall prevalence of HA V antibody was 43% (271/635) with the individual levels for the three institutions being 65% (institution A), 30% (institution B) and 68% (institution C) respectively. The differences were statistically significant (p<0.05). The in iti al results were equivocal for 41 samples so these were repeated. One patient whose result was equivocal had died in the interim period. A comparison of antibody by age group in this study and in the population study 6 is shown in Figure I . A comparison test between the two studies found no significant difference in overall antibody prevalence but there was an obvious difference in the 0-9 year age group. 
... ~
The prevalence of antibody in those living at home was 25% compared to 60% for those living in either an institution or a community dwelling (p<O.OOI).The distribution of HA V antibody status with respect to the variables in the questionnaire is shown in Table 2 . Univariate logistic regression is outlined in Table 3 . Multivariate logistic regression analysis for the entire study group and for those living at home is outlined in Tables 43 and 4b respectively. The only factor significant ly associated with prevalence of HA V antibody on multivariate analysis for the whole group was age. Among those living at home, in addition to age, the use of respite care was also associated with prevalence of antibody.
• An explanation or some or the terms used to Tables 2-4b is outlined below Confidence inlerval: A confidence interval provides a range of plausible values for the unknown parameter. These are usually quoted as 95% intervals, which are constructed so that one can be 95% confident that the true value of the unknown parameter lies between the limits.
Odd.~ ral;o: The odds in favou r of being exposed in subjects with the target disorder divided by the odds in favour of being exposed in those without the target disorder.
P va/lie:
This provides a standardised estimate of the likelihood of encountering values if there were no difference or effect. ,.
Discussion
We examined the prevalence of antibody and risk factors for HAV antibody i~ those ,with an intellectual disability in three centres in lreland. The rate is much lower than In an Insh nonresidential learning disability setting in the early 19905 II, The overall level of 10% among those aged 3 to 18 years in special schools in 1999 is similar to the rate of 10.9% found in those aged 0-\9 years in this study 12 • OUT overall response rate was good, the prevalence of HA V may have been somewhat underestimated in institution C as the non-responders there were older and the overall response rate for that institution was poorer. The epidemiology of HA V has changed fundamentally with the advent of hepatitis A vaccine. Before that, it was primarily cyclical but this is now changing in the US 25, the UK and Scandinavia 26, We are not yet in a position to say whether this cyclical pattern has also disappeared in Ireland. We note that the rates have been at their lowest level over the past four to five years but we do not know what will happen to the cyclical pattern in the years to come.
As in the population study in the provincial town 6 and the prevalence study in the special schools 12 oral fluid (salivary) sampling was used to assess the prevalence of antibody in this study. Individuals, including patients can collect saliva in a non-invasive manner with modest training 27 . This method was found to be acceptable to the clients in this study and avoids the need for blood letting which may be difficult in these circumstances. It is simple and rapid 23. There is a paucity of studies available 00 this topic and many of those available are old. Comparisons may not be valid given the change in social circumstances. The overall prevalence of antibody of 43% is similar to that found in two US studies 14, 11 in 1970 and in 1994-95. Given the overall decline in the prevalence of HA V in recent decades, the timing of the various studies will have a very significant impact on the antibody level. The only European studies found in the intellectual disability setting were in France (1992-3: anti-HA V prevalence of 50%) and in Spain (1996-7:54%) 16, 18 . These rates were marginally higher than we found but the Spanish study was carried out in an area of intennediate endem icity.
As found previously. the prevalence of antibody in this study sign ificantly increased with age 10, 1). \1 on both univariate and t analysis. While a number of factors were significantly assoc iated with anti-HA V on both univariate and t analysis, the only factor significantly associated with anti-HA Von multivariate logistic regression analysis for the whole group was age reflecting the fact that people do not lose their immunity and that older people are more likely to have been infected during their lifetime. Down syndrome was found to be negatively associated contrary to the findings of other studies 9.1). In countries with a low prevalence of anti-HAY, studies have found a close correlation with age and duration of institutionalisation and a high prevalence of HA V in institutionalised intellectually disabled patients 10, Il, u. Among those living at home, both age and the use of respite care were significantly associated with HA V antibody.
Neither the World Health Organization nor the Centers for Disease Control Atlanta lists people in institutions for intellectual disabilities as a high·risk group needing v~ccinatio~ with h "" A . 25 29 H h" ' " cpatltlS vacclOe . . owever, t IS C lent group is vaccinated in a number of European countries a~cording. to the findings of the EUROHEP.NET project 30 . A large US study conducted 10 the mid 1990s concluded that the current need for such an intervention is not clearly demonstrated 11. Changes in living arrangements, universal precautions and other changes may have substantially decreased the contemporary risk for HAV 11. While acknowledging that the population prevalence study was done IS years ago, there was a much higher prevalence of antibody in the 0-9 year age group in our study. It would be useful to have ongoing seroprevalence studies for the Irish population.
The primary course of the combined vaccine (3 doses) for an adult currently costs €102.84 compared with €57.15 for hepatitis B vaccine (GlaxoSmithKline, personal communication, March 2(06). The equivalent paediatric costs are €57.15 and €41.88 respectively. Therefore, the differential is very small for the pediatric vaccine. As it is current policy that those attending intellectual disability services receive hepatitis B vaccine 19 , and given the higher level of immunity in this study in the 0-9 years age group in comparison to the previous population study 6 , consideration should be given to offering new entrants the combination vaccine. A high uptake of the combined vaccine among special schools' pupils was achieved with one school having an 86% uptake of first and second dose (n= 19) and the second having a 97% uptake (n=30). The third school was offered hepatitis A vaccine only in response to an outbreak 12. This vaccine is safe and easy to administer with hepatitis B 3 1. It must be remembered that a single lapse of appropriate hygiene during exposure to the virus is sufficient to cause infection 20. These results will be available to Irish vaccination makers and thus can be used to fonnulate policy. In particular, we recommend that consideration should be given to immunising new entrants to the intellectual disability service with the combined hepatitis A and B vaccine. In the interim, strict hygiene and infection control polices should be maintained in the work and living areas of those with an intellectual disability. 
